Difference between revisions of "Talk:Assessment of the health impacts of H1N1 vaccination/Group C"

Resolution: Resolution not yet found.

(A stable resolution, when found, should be updated to the main page.)

⇤1 : Despite risks, Pandemrix is an effective vaccine and has clearly net positive effects in countries where emergency treatment is poorly available for severe swine flu cases. --Jouni 23:05, 31 March 2011 (EEST)

←2 : In a review by the U.S. National Institutes of Health, the 2009 flu pandemic vaccines appear both effective and safe, having a similar safety profile to the normal seasonal influenza vaccine. --Jpmannikko 17:00, 4 April 2011 (EEST)

⇤3 : According to CDC Pandemrix is not licenced for use in the United States. --Jpmannikko 17:15, 4 April 2011 (EEST)

⇤4 : Arepanrix, a H1N1 influenza vaccine similar to Pandemrix and also made by GSK was used in Canada. There has been no increase in narcolepsy cases in Canada reported. --Jpmannikko 17:15, 4 April 2011 (EEST)

←3 : The reputation of Pandemrix is globally so poor that it is impossible to use it any more. --Jouni 23:05, 31 March 2011 (EEST)

←4 : In Finland, THL decided to stop the use of Pandemrix. --Jouni 23:05, 31 March 2011 (EEST), [1]

⇤5 : Kari Välimäki, Chief of staff at the Ministry of Social Affairs and Health argues, that the suspension of Pandemrix is only a precautionary action, and that there is no doubt that in a similar situation, the same decisions would have been made. --Jpmannikko 16:55, 4 April 2011 (EEST)

←6 : There have been claims that THL would have had a conflict of interest, as it had received financing worth EUR 6 million from the vaccine producer GalaxoSmithKline (GSK) --Jpmannikko 16:51, 4 April 2011 (EEST)

⇤7 : The World Health Organization (WHO) examined the link between THL and GSK and found no evidence that research funding and the pharmaceutical company would have influenced the choise of vaccines --Jpmannikko 16:51, 4 April 2011 (EEST)